TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW 26
1.4 LIMITATIONS 28
1.5 MARKETS COVERED 28
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 CURRENCY AND PRICING 32
2.5 DBMR TRIPOD DATA VALIDATION MODEL 33
2.6 MULTIVARIATE MODELLING 36
2.7 CARDIAC MONITORING DEVICES LIFELINE CURVE 36
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.9 DBMR MARKET POSITION GRID 38
2.10 MARKET APPLICATION COVERAGE GRID 39
2.11 VENDOR SHARE ANALYSIS 40
2.12 SECONDARY SOURCES 41
2.13 ASSUMPTIONS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 45
4.1 PORTERS FIVE FORCES 46
4.2 VALUE CHAIN ANALYSIS: 47
4.3 COMPETITIVE ANALYSIS 48
4.4 BRAND ANALYSIS 50
4.5 ECOSYSTEM MAPS 51
4.6 TECHNOLOGICAL TRENDS 52
4.7 TOP WINNING STRATEGIES 53
5 MARKET OVERVIEW 54
5.1 DRIVERS 56
5.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES 56
5.1.2 GROWTH IN TECHNOLOGICAL ADVANCEMENTS 56
5.1.3 INCREASING DEMAND FOR REMOTE PATIENT MONITORING 58
5.1.4 INCREASING GOVERNMENT INITIATIVES 58
5.2 RESTRAINTS 59
5.2.1 STRICT REGULATORY FRAMEWORK 59
5.2.2 LACK OF STANDARDIZATION 60
5.3 OPPORTUNITIES 60
5.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 60
5.3.2 PROVIDES QUICK AND REAL TIME RESULTS 61
5.4 CHALLENGES 62
5.4.1 LACK OF SKILLED PROFESSIONALS 62
5.4.2 RISK TO PATIENT'S DATA SECURITY 62
6 NORTH AMERICA REMOTE PATIENT MONITORING AND CARE MARKET, BY DEVICE TYPE 64
6.1 OVERVIEW 65
6.2 CARDIAC MONITORING DEVICES 68
6.3 BLOOD PRESSURE MONITORING DEVICES 69
6.4 MULTI-PARAMETER MONITORING DEVICES 70
6.5 BLOOD GLUCOSE MONITORING DEVICES 71
6.6 RESPIRATORY MONITORING DEVICES 72
6.7 NEUROLOGICAL MONITORING DEVICES 73
6.8 OTHERS 74
7 NORTH AMERICA REMOTE PATIENT MONITORING AND CARE MARKET, BY APPLICATION 75
7.1 OVERVIEW 76
7.2 CARDIOVASCULAR DISEASE 79
7.2.1 CORONARY HEART DISEASE 80
7.2.2 STROKE 80
7.2.3 PERIPHERAL ARTERIAL DISEASE 80
7.2.4 AORTIC DISEASE 80
7.2.5 OTHERS 80
7.3 DIABETES 80
7.4 ONCOLOGY 81
7.5 OTHERS 82
8 NORTH AMERICA REMOTE PATIENT MONITORING AND CARE MARKET, BY END USER 83
8.1 OVERVIEW 84
8.2 HOME HEALTHCARE PATIENTS 87
8.2.1 BLOOD GLUCOSE MONITORING DEVICES 88
8.2.2 CARDIAC MONITORING DEVICES 88
8.2.3 BLOOD PRESSURE MONITORING DEVICES 88
8.2.4 MULTI-PARAMETER MONITORING DEVICES 88
8.2.5 RESPIRATORY MONITORING DEVICES 88
8.2.6 NEUROLOGICAL MONITORING DEVICES 88
8.2.7 OTHERS 89
8.3 AMBULATORY PATIENTS 89
8.3.1 MULTI-PARAMETER MONITORING DEVICES 90
8.3.2 RESPIRATORY MONITORING DEVICES 90
8.3.3 CARDIAC MONITORING DEVICES 90
8.3.4 BLOOD PRESSURE MONITORING DEVICES 90
8.3.5 BLOOD GLUCOSE MONITORING DEVICES 90
8.3.6 NEUROLOGICAL MONITORING DEVICES 90
8.3.7 OTHERS 91
8.4 HOSPITAL-BASED PATIENTS 91
8.4.1 MULTI-PARAMETER MONITORING DEVICES 92
8.4.2 CARDIAC MONITORING DEVICES 92
8.4.3 RESPIRATORY MONITORING DEVICES 92
8.4.4 BLOOD PRESSURE MONITORING DEVICES 92
8.4.5 BLOOD GLUCOSE MONITORING DEVICES 92
8.4.6 NEUROLOGICAL MONITORING DEVICES 92
8.4.7 OTHERS 93
9 NORTH AMERICA REMOTE PATIENT MONITORING AND CARE MARKET, BY REGION 94
9.1 NORTH AMERICA 95
9.1.1 U.S. 103
9.1.2 CANADA 107
9.1.3 MEXICO 111
10 NORTH AMERICA REMOTE PATIENT MONITORING AND CARE MARKET, COMPANY LANDSCAPE 115
10.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 115
11 SWOT ANALYSIS 116
12 COMPANY PROFILE 117
12.1 MEDTRONIC 117
12.1.1 COMPANY SNAPSHOT 117
12.1.2 REVENUE ANALYSIS 118
12.1.3 COMPANY SHARE ANALYSIS 118
12.1.4 PRODUCT PORTFOLIO 119
12.1.5 RECENT DEVELOPMENT 119
12.2 DEXCOM, INC. 120
12.2.1 COMPANY SNAPSHOT 120
12.2.2 REVENUE ANALYSIS 120
12.2.3 COMPANY SHARE ANALYSIS 121
12.2.4 PRODUCT PORTFOLIO 121
12.2.5 RECENT DEVELOPMENT 121
12.3 ABBOTT 122
12.3.1 COMPANY SNAPSHOT 122
12.3.2 REVENUE ANALYSIS 122
12.3.3 COMPANY SHARE ANALYSIS 123
12.3.4 PRODUCT PORTFOLIO 123
12.3.5 RECENT DEVELOPMENT 123
12.4 RESMED 124
12.4.1 COMPANY SNAPSHOT 124
12.4.2 REVENUE ANALYSIS 124
12.4.3 COMPANY SHARE ANALYSIS 125
12.4.4 PRODUCT PORTFOLIO 125
12.4.5 RECENT DEVELOPMENT 125
12.5 BIOTRONIK SE & CO. KG 126
12.5.1 COMPANY SNAPSHOT 126
12.5.2 COMPANY SHARE ANALYSIS 126
12.5.3 PRODUCT PORTFOLIO 127
12.5.4 RECENT DEVELOPMENT 127
12.6 100 PLUS. 128
12.6.1 COMPANY SNAPSHOT 128
12.6.2 PRODUCT PORTFOLIO 128
12.6.3 RECENT DEVELOPMENTS 128
12.7 A&D COMPANY, LIMITED 129
12.7.1 COMPANY SNAPSHOT 129
12.7.2 REVENUE ANALYSIS 129
12.7.3 COMPANY SHARE ANALYSIS 130
12.7.4 PRODUCT PORTFOLIO 130
12.7.5 RECENT DEVELOPMENT 130
12.8 AEROTEL MEDICAL SYSTEMS 131
12.8.1 COMPANY SNAPSHOT 131
12.8.2 PRODUCT PORTFOLIO 131
12.8.3 RECENT DEVELOPMENT 131
12.9 ALIVECOR, INC. 132
12.9.1 COMPANY SNAPSHOT 132
12.9.2 COMPANY SHARE ANALYSIS 132
12.9.3 PRODUCT PORTFOLIO 132
12.9.4 RECENT DEVELOPMENTS 133
12.10 BIOBEAT 134
12.10.1 COMPANY SNAPSHOT 134
12.10.2 PRODUCT PORTFOLIO 134
12.10.3 RECENT DEVELOPMENT 134
12.11 BOSTON SCIENTIFIC CORPORATION 135
12.11.1 COMPANY SNAPSHOT 135
12.11.2 REVENUE ANALYSIS 136
12.11.3 COMPANY SHARE ANALYSIS 136
12.11.4 PRODUCT PORTFOLIO 136
12.11.5 RECENT DEVELOPMENT 137
12.12 CARDIOMO 138
12.12.1 COMPANY SNAPSHOT 138
12.12.2 PRODUCT PORTFOLIO 138
12.12.3 RECENT DEVELOPMENTS 138
12.13 CHRONISENSE MEDICAL, LTD. 139
12.13.1 COMPANY SNAPSHOT 139
12.13.2 PRODUCT PORTFOLIO 139
12.13.3 RECENT DEVELOPMENT 139
12.14 COACHCARE 140
12.14.1 COMPANY SNAPSHOT 140
12.14.2 PRODUCT PORTFOLIO 140
12.14.3 RECENT DEVELOPMENT 140
12.15 GENERAL ELECTRIC 141
12.15.1 COMPANY SNAPSHOT 141
12.15.2 REVENUE ANALYSIS 141
12.15.3 COMPANY SHARE ANALYSIS 142
12.15.4 PRODUCT PORTFOLIO 142
12.15.5 RECENT DEVELOPMENT 142
12.16 KONINKLIJKE PHILIPS N.V. 143
12.16.1 COMPANY SNAPSHOT 143
12.16.2 REVENUE ANALYSIS 143
12.16.3 COMPANY SHARE ANALYSIS 144
12.16.4 PRODUCT PORTFOLIO 144
12.16.5 RECENT DEVELOPMENT 144
12.17 MASIMO 145
12.17.1 COMPANY SNAPSHOT 145
12.17.2 REVENUE ANALYSIS 145
12.17.3 COMPANY SHARE ANALYSIS 146
12.17.4 PRODUCT PORTFOLIO 146
12.17.5 RECENT DEVELOPMENT 146
12.18 NETEERA 147
12.18.1 COMPANY SNAPSHOT 147
12.18.2 PRODUCT PORTFOLIO 147
12.18.3 RECENT DEVELOPMENT 147
12.19 NIHON KOHDEN CORPORATION 148
12.19.1 COMPANY SNAPSHOT 148
12.19.2 REVENUE ANALYSIS 148
12.19.3 COMPANY SHARE ANALYSIS 149
12.19.4 PRODUCT PORTFOLIO 149
12.19.5 RECENT DEVELOPMENT 149
12.20 OMRON CORPORATION 150
12.20.1 COMPANY SNAPSHOT 150
12.20.2 REVENUE ANALYSIS 150
12.20.3 COMPANY SHARE ANALYSIS 151
12.20.4 PRODUCT PORTFOLIO 151
12.20.5 RECENT DEVELOPMENT 151
12.21 SENSEONICS, INC. 152
12.21.1 COMPANY SNAPSHOT 152
12.21.2 REVENUE ANALYSIS 152
12.21.3 COMPANY SHARE ANALYSIS 153
12.21.4 PRODUCT PORTFOLIO 153
12.21.5 RECENT DEVELOPMENT 153
12.22 VITALCONNECT 154
12.22.1 COMPANY SNAPSHOT 154
12.22.2 PRODUCT PORTFOLIO 154
12.22.3 RECENT DEVELOPMENT 154
12.23 VITLS 155
12.23.1 COMPANY SNAPSHOT 155
12.23.2 PRODUCT PORTFOLIO 155
12.23.3 RECENT DEVELOPMENT 155
12.24 VIVIFY HEALTH INC. 156
12.24.1 COMPANY SNAPSHOT 156
12.24.2 PRODUCT PORTFOLIO 156
12.24.3 RECENT DEVELOPMENTS 156
12.25 WITHINGS 157
12.25.1 COMPANY SNAPSHOT 157
12.25.2 COMPANY SHARE ANALYSIS 157
12.25.3 PRODUCT PORTFOLIO 157
12.25.4 RECENT DEVELOPMENT 158
13 QUESTIONNAIRE 159
14 RELATED REPORTS 162

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.